Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Primary Immunodeficiencies Unravel the Role of IL-2/CD25/STAT5b in Human Natural Killer Cell Maturation.

Caldirola MS, Rodríguez Broggi MG, Gaillard MI, Bezrodnik L, Zwirner NW.

Front Immunol. 2018 Jun 22;9:1429. doi: 10.3389/fimmu.2018.01429. eCollection 2018.

2.

Interleukin (IL)-23 Stimulates IFN-γ Secretion by CD56bright Natural Killer Cells and Enhances IL-18-Driven Dendritic Cells Activation.

Ziblat A, Nuñez SY, Raffo Iraolagoitia XL, Spallanzani RG, Torres NI, Sierra JM, Secchiari F, Domaica CI, Fuertes MB, Zwirner NW.

Front Immunol. 2018 Jan 17;8:1959. doi: 10.3389/fimmu.2017.01959. eCollection 2017.

3.

Human M2 Macrophages Limit NK Cell Effector Functions through Secretion of TGF-β and Engagement of CD85j.

Nuñez SY, Ziblat A, Secchiari F, Torres NI, Sierra JM, Raffo Iraolagoitia XL, Araya RE, Domaica CI, Fuertes MB, Zwirner NW.

J Immunol. 2018 Feb 1;200(3):1008-1015. doi: 10.4049/jimmunol.1700737. Epub 2017 Dec 27.

4.

CD4+ T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C virus-coinfected patients.

Laufer N, Ojeda D, Polo ML, Martinez A, Pérez H, Turk G, Cahn P, Zwirner NW, Quarleri J.

World J Hepatol. 2017 Sep 8;9(25):1073-1080. doi: 10.4254/wjh.v9.i25.1073.

5.

Regulation of NK Cell Activation and Effector Functions by the IL-12 Family of Cytokines: The Case of IL-27.

Zwirner NW, Ziblat A.

Front Immunol. 2017 Jan 19;8:25. doi: 10.3389/fimmu.2017.00025. eCollection 2017. Review.

6.

Predictive Outcomes for HER2-enriched Cancer Using Growth and Metastasis Signatures Driven By SPARC.

Güttlein LN, Benedetti LG, Fresno C, Spallanzani RG, Mansilla SF, Rotondaro C, Raffo Iraolagoitia XL, Salvatierra E, Bravo AI, Fernández EA, Gottifredi V, Zwirner NW, Llera AS, Podhajcer OL.

Mol Cancer Res. 2017 Mar;15(3):304-316. doi: 10.1158/1541-7786.MCR-16-0243-T. Epub 2016 Dec 28.

7.

NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.

Iraolagoitia XL, Spallanzani RG, Torres NI, Araya RE, Ziblat A, Domaica CI, Sierra JM, Nuñez SY, Secchiari F, Gajewski TF, Zwirner NW, Fuertes MB.

J Immunol. 2016 Aug 1;197(3):953-61. doi: 10.4049/jimmunol.1502291. Epub 2016 Jun 24.

8.

Expression and Functional Role of α7 Nicotinic Receptor in Human Cytokine-stimulated Natural Killer (NK) Cells.

Zanetti SR, Ziblat A, Torres NI, Zwirner NW, Bouzat C.

J Biol Chem. 2016 Aug 5;291(32):16541-52. doi: 10.1074/jbc.M115.710574. Epub 2016 Jun 9.

9.

Regulatory Dendritic Cells Restrain NK Cell IFN-γ Production through Mechanisms Involving NKp46, IL-10, and MHC Class I-Specific Inhibitory Receptors.

Spallanzani RG, Torres NI, Avila DE, Ziblat A, Iraolagoitia XL, Rossi LE, Domaica CI, Fuertes MB, Rabinovich GA, Zwirner NW.

J Immunol. 2015 Sep 1;195(5):2141-8. doi: 10.4049/jimmunol.1403161. Epub 2015 Jul 31.

10.

IL-27 stimulates human NK-cell effector functions and primes NK cells for IL-18 responsiveness.

Ziblat A, Domaica CI, Spallanzani RG, Iraolagoitia XL, Rossi LE, Avila DE, Torres NI, Fuertes MB, Zwirner NW.

Eur J Immunol. 2015 Jan;45(1):192-202. doi: 10.1002/eji.201444699. Epub 2014 Dec 2.

11.

Expansion of CD11b(+)Ly6G (+)Ly6C (int) cells driven by medroxyprogesterone acetate in mice bearing breast tumors restrains NK cell effector functions.

Spallanzani RG, Dalotto-Moreno T, Raffo Iraolagoitia XL, Ziblat A, Domaica CI, Avila DE, Rossi LE, Fuertes MB, Battistone MA, Rabinovich GA, Salatino M, Zwirner NW.

Cancer Immunol Immunother. 2013 Dec;62(12):1781-95. doi: 10.1007/s00262-013-1483-x. Epub 2013 Oct 11.

PMID:
24114144
12.

Broad MICA/B expression in the small bowel mucosa: a link between cellular stress and celiac disease.

Allegretti YL, Bondar C, Guzman L, Cueto Rua E, Chopita N, Fuertes M, Zwirner NW, Chirdo FG.

PLoS One. 2013 Sep 13;8(9):e73658. doi: 10.1371/journal.pone.0073658. eCollection 2013.

13.

Human natural killer cell maturation defect supports in vivo CD56(bright) to CD56(dim) lineage development.

Domaica CI, Fuertes MB, Uriarte I, Girart MV, Sardañons J, Comas DI, Di Giovanni D, Gaillard MI, Bezrodnik L, Zwirner NW.

PLoS One. 2012;7(12):e51677. doi: 10.1371/journal.pone.0051677. Epub 2012 Dec 11.

14.

Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression.

Rossi LE, Avila DE, Spallanzani RG, Ziblat A, Fuertes MB, Lapyckyj L, Croci DO, Rabinovich GA, Domaica CI, Zwirner NW.

J Leukoc Biol. 2012 Feb;91(2):321-31. doi: 10.1189/jlb.0711339. Epub 2011 Nov 28.

PMID:
22124136
15.

Premalignant quiescent melanocytic nevi do not express the MHC class I chain-related protein A.

Fuertes MB, Rossi LE, Peralta CM, Cabrera HN, Allevato MA, Zwirner NW.

Medicina (B Aires). 2011;71(4):357-60.

PMID:
21893449
16.

Nuclear factor (NF)-κB controls expression of the immunoregulatory glycan-binding protein galectin-1.

Toscano MA, Campagna L, Molinero LL, Cerliani JP, Croci DO, Ilarregui JM, Fuertes MB, Nojek IM, Fededa JP, Zwirner NW, Costas MA, Rabinovich GA.

Mol Immunol. 2011 Sep;48(15-16):1940-9. doi: 10.1016/j.molimm.2011.05.021.

PMID:
21689853
17.

Cytokine regulation of natural killer cell effector functions.

Zwirner NW, Domaica CI.

Biofactors. 2010 Jul-Aug;36(4):274-88. doi: 10.1002/biof.107. Review.

PMID:
20623510
18.

Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells.

Zwirner NW, Croci DO, Domaica CI, Rabinovich GA.

Curr Pharm Des. 2010 Jan;16(3):255-67. Review.

PMID:
20109135
19.

Tumour-experienced T cells promote NK cell activity through trogocytosis of NKG2D and NKp46 ligands.

Domaica CI, Fuertes MB, Rossi LE, Girart MV, Avila DE, Rabinovich GA, Zwirner NW.

EMBO Rep. 2009 Aug;10(8):908-15. doi: 10.1038/embor.2009.92. Epub 2009 Jun 5.

20.

Immunology south of the equator in the Americas.

Rabinovich GA, Kalergis AM, Zwirner NW, Savino W.

Nat Immunol. 2008 Oct;9(10):1087-90. doi: 10.1038/ni1008-1087. Review.

PMID:
18800156
21.

Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity.

Fuertes MB, Girart MV, Molinero LL, Domaica CI, Rossi LE, Barrio MM, Mordoh J, Rabinovich GA, Zwirner NW.

J Immunol. 2008 Apr 1;180(7):4606-14.

22.
23.

Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death.

Toscano MA, Bianco GA, Ilarregui JM, Croci DO, Correale J, Hernandez JD, Zwirner NW, Poirier F, Riley EM, Baum LG, Rabinovich GA.

Nat Immunol. 2007 Aug;8(8):825-34. Epub 2007 Jun 24.

PMID:
17589510
24.

Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system.

Zwirner NW, Fuertes MB, Girart MV, Domaica CI, Rossi LE.

Cytokine Growth Factor Rev. 2007 Feb-Apr;18(1-2):159-70. Epub 2007 Feb 26. Review.

PMID:
17324607
25.

Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity.

Molinero LL, Domaica CI, Fuertes MB, Girart MV, Rossi LE, Zwirner NW.

Hum Immunol. 2006 Mar;67(3):170-82. Epub 2006 Mar 31.

PMID:
16698439
26.

Regulated expression of galectin-1 during T-cell activation involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase and p70S6 kinase.

Fuertes MB, Molinero LL, Toscano MA, Ilarregui JM, Rubinstein N, Fainboim L, Zwirner NW, Rabinovich GA.

Mol Cell Biochem. 2004 Dec;267(1-2):177-85.

PMID:
15663199
27.

NF-kappa B regulates expression of the MHC class I-related chain A gene in activated T lymphocytes.

Molinero LL, Fuertes MB, Girart MV, Fainboim L, Rabinovich GA, Costas MA, Zwirner NW.

J Immunol. 2004 Nov 1;173(9):5583-90.

28.

Cloning, expression and interaction of human T-cell receptors with the bacterial superantigen SSA.

De Marzí MC, Fernández MM, Sundberg EJ, Molinero L, Zwirner NW, Llera AS, Mariuzza RA, Malchiodi EL.

Eur J Biochem. 2004 Oct;271(20):4075-83.

30.

Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege.

Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA.

Cancer Cell. 2004 Mar;5(3):241-51.

31.

Up-regulated expression of MICA on activated T lymphocytes involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase, and calcineurin.

Molinero LL, Fuertes MB, Fainboim L, Rabinovich GA, Zwirner NW.

J Leukoc Biol. 2003 Jun;73(6):815-22.

PMID:
12773514
32.

Up-regulated expression of MICA and proinflammatory cytokines in skin biopsies from patients with seborrhoeic dermatitis.

Molinero LL, Gruber M, Leoni J, Woscoff A, Zwirner NW.

Clin Immunol. 2003 Jan;106(1):50-4.

PMID:
12584051
33.

Codominant expression of the polymorphic MICA alloantigens encoded by genes in the HLA region.

Molinero LL, Marcos CY, Mirbaha F, Fainboim L, Stastny P, Zwirner NW.

Eur J Immunogenet. 2002 Aug;29(4):315-9.

PMID:
12121277
34.

Activation-induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28.

Molinero LL, Fuertes MB, Rabinovich GA, Fainboim L, Zwirner NW.

J Leukoc Biol. 2002 May;71(5):791-7.

PMID:
11994503
35.

In vitro presentation of gliadin-derived peptides by different cell lines.

Chirdo FG, Zwirner NW, Rumbo M, Fossati CA.

Clin Chim Acta. 2002 Mar;317(1-2):151-8.

PMID:
11814470
36.

Identification of MICA as a new polymorphic alloantigen recognized by antibodies in sera of organ transplant recipients.

Zwirner NW, Marcos CY, Mirbaha F, Zou Y, Stastny P.

Hum Immunol. 2000 Sep;61(9):917-24.

PMID:
11053635
37.

Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes.

Zwirner NW, Dole K, Stastny P.

Hum Immunol. 1999 Apr;60(4):323-30.

PMID:
10363723
38.

Juvenile arthritis, HLA-A2 and binding of DEK oncogene-peptides.

Forero L, Zwirner NW, Fink CW, Fernández-Viña MA, Stastny P.

Hum Immunol. 1998 Jul;59(7):443-50.

PMID:
9684994
39.

MICA, a new polymorphic HLA-related antigen, is expressed mainly by keratinocytes, endothelial cells, and monocytes.

Zwirner NW, Fernández-Viña MA, Stastny P.

Immunogenetics. 1998;47(2):139-48.

PMID:
9396860
40.

Trypanosoma cruzi and Leishmania spp. human mixed infection.

Chiaramonte MG, Zwirner NW, Caropresi SL, Taranto NJ, Malchiodi EL.

Am J Trop Med Hyg. 1996 Mar;54(3):271-3.

PMID:
8600764
41.

[Study of cases of leishmaniasis in the Province of Salta: evidences of mixed infection with Trypanosoma cruzi and Leishmania spp].

Chiaramonte MG, Zwirner NW, Caropresi SL, Heredia V, Taranto NJ, Malchiodi EL.

Medicina (B Aires). 1996;56(3):259-68. Spanish.

PMID:
9035482
42.

Modulation of cardiac physiology by an anti-Trypanosoma cruzi monoclonal antibody after interaction with myocardium.

Cremaschi G, Zwirner NW, Gorelik G, Malchiodi EL, Chiaramonte MG, Fossati CA, Sterin-Borda L.

FASEB J. 1995 Nov;9(14):1482-8.

PMID:
7589990
44.
45.

Identity of the major cysteine proteinase (cruzipain) from Trypanosoma cruzi and an antigen (Ag163B6) isolated with a monoclonal antibody.

Malchiodi EL, Chiaramonte MG, Martínez JA, Zwirner NW, Margni RA, Cazzulo JJ.

Immunol Lett. 1993 Jan;35(1):59-62.

PMID:
8458637
46.

[Use of formalinized epimastigotes for the detection of anti-Trypanosoma cruzi antibodies using immunoenzyme technics].

Carbonetto CH, Malchiodi EL, Chiaramonte MG, Zwirner NW, Margni RA.

Rev Argent Microbiol. 1989 Apr-Jun;21(2):79-83. Spanish.

PMID:
2694219

Supplemental Content

Loading ...
Support Center